Advertisement

Fas Signaling pp 145-156 | Cite as

Tools for Activation and Neutralization of Fas Signaling

  • Pascal Schneider
Chapter
  • 255 Downloads
Part of the Medical Intelligence Unit book series (MIUN)

Abstract

Apoptosis mediated by the Fas / FasL pair of receptor and ligand is involved in physiological or pathological processes in which cell death is either required to eliminate potentially harmful infected, transformed or autoreactive cells, or is detrimental when healthy cells like hepatocytes are massively killed. Since the discovery of cytotoxic anti-Fas antibodies, agonists and antagonists of Fas and FasL have not only proven essential tools for this field of research, but also provided clues on the molecular mechanism of Fas activation. In order to signal apoptosis, Fas not only requires to be engaged by FasL, but also needs to be so in a multivalent fashion. Hence, agents that prevent higher order multimerization of Fas act as antagonists, even if they do bind Fas. The inherent resistance of a cell to suboptimal Fas signals is another essential factor regarding the outcome of Fas engagement. This review discusses agonists and antagonists of the Fas pathway that act at the level of the extracellular domain of either Fas or FasL.

Keywords

Toxic Epidermal Necrolysis Cartilage Oligomeric Matrix Protein Soluble FasL Human FasL Recombinant FasL 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science Jul 21 1989; 245(4915):301–305.PubMedCrossRefGoogle Scholar
  2. 2.
    Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor. J Exp Med May 1 1989; 169(5):1747–1756.PubMedCrossRefGoogle Scholar
  3. 3.
    Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell Dec 17 1993; 75(6):1169–1178.PubMedCrossRefGoogle Scholar
  4. 4.
    Takahashi T, Tanaka M, Inazawa J et al. Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol Oct 1994; 6(10):1567–1574.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe-Fukunaga R, Brannan CI, Itoh N et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol Feb 15 1992; 148(4):1274–1279.PubMedGoogle Scholar
  6. 6.
    Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell Jul 26 1991; 66(2):233–243.PubMedCrossRefGoogle Scholar
  7. 7.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature Aug 26 1993; 364(6440):806–809.PubMedCrossRefGoogle Scholar
  8. 8.
    Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: Genetic defects of apoptosis pathways. Cell Death Differ Jan 2003; 10(1):124–133.PubMedCrossRefGoogle Scholar
  9. 9.
    Nagata S, Golstein P. The Fas death factor. Science Mar 10 1995; 267(5203):1449–1456.PubMedCrossRefGoogle Scholar
  10. 10.
    O’Connell J, Houston A, Bennett MW et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med Mar 2001; 7(3):271–274.CrossRefGoogle Scholar
  11. 11.
    Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ Jan 2003; 10(1):26–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Dhein J, Daniel PT, Trauth BC et al. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol Nov 15 1992; 149(10):3166–3173.PubMedGoogle Scholar
  13. 13.
    Fadeel B, Thorpe J, Chiodi F. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb. Int Immunol Dec 1995; 7(12):1967–1975.PubMedCrossRefGoogle Scholar
  14. 14.
    Fadeel B, Thorpe CJ, Yonehara S et al. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int Immunol 1997; 9(2):201–209.PubMedCrossRefGoogle Scholar
  15. 15.
    Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288(5475):2354–2357.PubMedCrossRefGoogle Scholar
  16. 16.
    Maeda T, Nakayama S, Yamada Y et al. The conformational alteration of the mutated extracellular domain of Fas in an adult T cell leukemia cell line. Biochem Biophys Res Commun Sep 6 2002; 296(5):1251–1256.PubMedCrossRefGoogle Scholar
  17. 17.
    Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood Dec 15 2001; 98(13):3860–3863.PubMedCrossRefGoogle Scholar
  18. 18.
    Ferrari D, Stepczynska A, Los M et al. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95-and anticancer drug-induced apoptosis. J Exp Med Sep 7 1998; 188(5):979–984.PubMedCrossRefGoogle Scholar
  19. 19.
    Schmidt M, Lugering N, Pauels HG et al. IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway. Eur J Immunol Jun 2000; 30(6):1769–1777.PubMedCrossRefGoogle Scholar
  20. 20.
    Silvestris F, Nagata S, Cafforio P et al. Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients. J Exp Med Dec 1 1996; 184(6):2287–2300.PubMedCrossRefGoogle Scholar
  21. 21.
    Nishimura Y, Ishii A, Kobayashi Y et al. Expression and function of mouse Fas antigen on immature and mature T cells. J Immunol May 1 1995; 154(9):4395–4403.PubMedGoogle Scholar
  22. 22.
    Nishimura Y, Hirabayashi Y, Matsuzaki Y et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol Feb 1997; 9(2):307–316.PubMedCrossRefGoogle Scholar
  23. 23.
    Ogawa Y, Kuwahara H, Kimura T et al. Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol May 2001; 28(5):950–955.PubMedGoogle Scholar
  24. 24.
    Suda T, Hashimoto H, Tanaka M et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 186(12):2045–2050.PubMedCrossRefGoogle Scholar
  25. 25.
    Tanaka M, Suda T, Takahashi T et al. Expression of the functional soluble form of human fas ligand in activated lymphocytes. Embo J Mar 15 1995; 14(6):1129–1135.PubMedGoogle Scholar
  26. 26.
    Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187(8):1205–1213.PubMedCrossRefGoogle Scholar
  27. 27.
    Kataoka T, Ito M, Budd RC et al. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells. Exp Cell Res Feb 15 2002; 273(2):256–264.PubMedCrossRefGoogle Scholar
  28. 28.
    Tanaka M, Itai T, Adachi M et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4(1):31–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Holler N, Tardivel A, Kovacsovics-Bankowski M et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol Feb 2003; 23(4):1428–1440.PubMedCrossRefGoogle Scholar
  30. 30.
    Suda T, Tanaka M, Miwa K et al. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 1996; 157(9):3918–3924.PubMedGoogle Scholar
  31. 31.
    Blott EJ, Bossi G, Clark R et al. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci Jul 2001; H4 (Pt 13):2405–2416.Google Scholar
  32. 32.
    Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nature Medicine 1996; 2(3):317–322.PubMedCrossRefGoogle Scholar
  33. 33.
    Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med Dec 1 1995; 182(6):1777–1783.PubMedCrossRefGoogle Scholar
  34. 34.
    Martinez-Lorenzo MJ, Anel A, Gamen S et al. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol Aug 1 1999; 163(3):1274–1281.PubMedGoogle Scholar
  35. 35.
    Jodo S, Strehlow D, Ju ST. Bioactivities of Fas ligand-expressing retroviral particles. J Immunol May 15 2000; 164(10):5062–5069.PubMedGoogle Scholar
  36. 36.
    Samel D, Muller D, Gerspach J et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem Aug 22 2003; 278(34):32077–32082.PubMedCrossRefGoogle Scholar
  37. 37.
    Ashkenazi A, Chamow SM. Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol Apr 1997; 9(2):195–200.PubMedCrossRefGoogle Scholar
  38. 38.
    Miwa K, Hashimoto H, Yatomi T et al. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol Jun 1999; 11(6):925–931.PubMedCrossRefGoogle Scholar
  39. 39.
    Holler N, Kataoka T, Bodmer JL et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237(1–2):159–173.PubMedCrossRefGoogle Scholar
  40. 40.
    Mahiou J, Walter U, Lepault F et al. In vivo blockade of the Fas-Fas ligand pathway inhibits cyclophosphamide-induced diabetes in NOD mice. J Autoimmun Jun 2001; 16(4):431–440.PubMedCrossRefGoogle Scholar
  41. 41.
    Kondo T, Suda T, Fukuyama H et al. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3(4):409–413.PubMedCrossRefGoogle Scholar
  42. 42.
    Ueno Y, Ishii M, Yahagi K et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology Apr 2000; 31(4):966–974.PubMedCrossRefGoogle Scholar
  43. 43.
    Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science Mar 25 1994; 263(5154):1759–1762.PubMedCrossRefGoogle Scholar
  44. 44.
    Proussakova OV, Rabaya NA, Moshnikova AB et al. Oligomerization of soluble Fas antigen in-duces its cytotoxicity. J Biol Chem Sep 19 2003; 278(38):36236–36241.PubMedCrossRefGoogle Scholar
  45. 45.
    Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature Dec 17 1998; 396(6712):699–703.PubMedCrossRefGoogle Scholar
  46. 46.
    Yu KY, Kwon B, Ni J et al. A newly identified member of tumor necrosis factor receptor super-family (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem May 14 1999; 274(20):13733–13736.PubMedCrossRefGoogle Scholar
  47. 47.
    Migone TS, Zhang J, Luo X et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16(3):479–492.PubMedCrossRefGoogle Scholar
  48. 48.
    Wroblewski VJ, McCloud C, Davis K et al. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos Apr 2003; 31(4):502–507.PubMedCrossRefGoogle Scholar
  49. 49.
    Wortinger MA, Foley JW, Larocque P et al. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology Oct 2003; 110(2):225–233.PubMedCrossRefGoogle Scholar
  50. 50.
    Yonehara S, Nishimura Y, Kishil S et al. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int Immunol Dec 1994; 6(12):1849–1856.PubMedCrossRefGoogle Scholar
  51. 51.
    Komada Y, Inaba H, Li QS et al. Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies. Hybridoma Oct 1999; 18(5):391–398.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhang H, Cook J, Nickel J et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol Aug 2000; 18(8):862–867.PubMedCrossRefGoogle Scholar
  53. 53.
    Zhang H, Taylor J, Luther D et al. Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis. J Pharmacol Exp Ther Oct 2003; 307(1):24–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Ji J, Wernli M, Buechner S et al. Fas ligand downregulation with antisense oligonucleotides in cells and in cultured tissues of normal skin epidermis and basal cell carcinoma. J Invest Dermatol Jun 2003; 120(6):1094–1099.PubMedCrossRefGoogle Scholar
  55. 55.
    Schmidt M, Lugering N, Lugering A et al. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol Jan 15 2001; 166(2):1344–1351.PubMedGoogle Scholar
  56. 56.
    Mihara S, Suzuki N, Takeba Y et al. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Clin Exp Immunol. Aug 2002; 129(2):359–369.PubMedCrossRefGoogle Scholar
  57. 57.
    Kayagaki N, Yamaguchi N, Nagao F et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci USA Apr 15 1997; 94(8):3914–3919.PubMedCrossRefGoogle Scholar
  58. 58.
    Kim S, Kim KA, Hwang DY et al. Inhibition of autoimmune diabetes by Fas ligand: The paradox is solved. J Immunol Mar 15 2000; 164(6):2931–2936.PubMedGoogle Scholar
  59. 59.
    Martin-Villalba A, Hahne M, Kleber S et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8(7):679–686.PubMedCrossRefGoogle Scholar
  60. 60.
    Mitsiades N, Yu WH, Poulaki V et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res Jan 15 2001; 61(2):577–581.PubMedGoogle Scholar
  61. 61.
    Vargo-Gogola T, Crawford HC, Fingleton B et al. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys. Dec 15 2002; 408(2):155–161.PubMedCrossRefGoogle Scholar
  62. 62.
    Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282(5388):490–493.PubMedCrossRefGoogle Scholar
  63. 63.
    Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol Jan 2003; 139(1):26–32.PubMedCrossRefGoogle Scholar
  64. 64.
    Trent JT, Kirsner RS, Romanelli P et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol Jan 2003; 139(1):39–43.PubMedCrossRefGoogle Scholar
  65. 65.
    Mayorga C, Torres MJ, Corzo JL et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol Jul 2003; 91(1):86–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol Jan 2003; 139(1):33–36.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2006

Authors and Affiliations

  • Pascal Schneider
    • 1
  1. 1.Institute of BiochemistryUniversity of LausanneEpalingesSwitzerland

Personalised recommendations